Which has stronger earnings & valuation, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.10 $8.84B $1.91 22.35 Novartis $54.53B 5.37 $13.98B $6.63 23.13

Is SNY or NVS more profitable?

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Novartis 23.29% 38.56% 14.47%

Does the media refer more to SNY or NVS?

In the previous week, Sanofi had 10 more articles in the media than Novartis. MarketBeat recorded 28 mentions for Sanofi and 18 mentions for Novartis. Novartis' average media sentiment score of 1.21 beat Sanofi's score of 1.09 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Novartis 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, SNY or AZN?

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.10 $8.84B $1.91 22.35 Astrazeneca $58.74B 4.11 $10.23B $6.69 23.29

Is SNY or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to Sanofi's net margin of 8.66%. Astrazeneca's return on equity of 31.45% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to SNY or AZN?

In the previous week, Astrazeneca had 32 more articles in the media than Sanofi. MarketBeat recorded 60 mentions for Astrazeneca and 28 mentions for Sanofi. Sanofi's average media sentiment score of 1.09 beat Astrazeneca's score of 0.80 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Astrazeneca 33 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation and earnings, SNY or NVO?

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.10 $8.84B $1.91 22.35 Novo Nordisk A/S $46.80B 4.21 $15.51B $4.26 10.37

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 8.66%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media favor SNY or NVO?

In the previous week, Novo Nordisk A/S had 40 more articles in the media than Sanofi. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 28 mentions for Sanofi. Sanofi's average media sentiment score of 1.09 beat Novo Nordisk A/S's score of 0.35 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Novo Nordisk A/S 26 Very Positive mention(s) 13 Positive mention(s) 5 Neutral mention(s) 16 Negative mention(s) 6 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, SNY or GSK?

Sanofi has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.10 $8.84B $1.91 22.35 GSK $43.07B 2.42 $7.54B $3.20 16.12

Is SNY or GSK more profitable?

GSK has a net margin of 14.56% compared to Sanofi's net margin of 8.66%. GSK's return on equity of 43.23% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% GSK 14.56% 43.23% 11.60%

Does the media refer more to SNY or GSK?

In the previous week, Sanofi had 15 more articles in the media than GSK. MarketBeat recorded 28 mentions for Sanofi and 13 mentions for GSK. Sanofi's average media sentiment score of 1.09 beat GSK's score of 0.52 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive GSK 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ARGX or SNY?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.44 $1.29B $26.04 32.43 Sanofi $49.35B 2.10 $8.84B $1.91 22.35

Is ARGX or SNY more profitable?

argenex has a net margin of 32.19% compared to Sanofi's net margin of 8.66%. argenex's return on equity of 43.59% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Sanofi 8.66% 14.19% 7.95%

Does the media favor ARGX or SNY?

In the previous week, Sanofi had 11 more articles in the media than argenex. MarketBeat recorded 28 mentions for Sanofi and 17 mentions for argenex. Sanofi's average media sentiment score of 1.09 beat argenex's score of 0.91 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Sanofi (SNY) Competitors

$42.68 -0.27 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$42.78 +0.09 (+0.22%)

As of 05:12 PM Eastern

Compare

SNY vs. NVS, AZN, NVO, GSK, and ARGX

Should you buy Sanofi stock or one of its competitors? MarketBeat compares Sanofi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanofi include Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), GSK (GSK), and argenex (ARGX).

How does Sanofi compare to Novartis?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Novartis	23.29%	38.56%	14.47%

Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.35
Novartis	$54.53B	5.37	$13.98B	$6.63	23.13

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 46.5% of its earnings in the form of a dividend.

In the previous week, Sanofi had 10 more articles in the media than Novartis. MarketBeat recorded 28 mentions for Sanofi and 18 mentions for Novartis. Novartis' average media sentiment score of 1.21 beat Sanofi's score of 1.09 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Novartis	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanofi presently has a consensus price target of $49.50, indicating a potential upside of 15.98%. Novartis has a consensus price target of $141.20, indicating a potential downside of 7.94%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to Astrazeneca?

Sanofi (NASDAQ:SNY) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 64.9% of its earnings in the form of a dividend.

In the previous week, Astrazeneca had 32 more articles in the media than Sanofi. MarketBeat recorded 60 mentions for Astrazeneca and 28 mentions for Sanofi. Sanofi's average media sentiment score of 1.09 beat Astrazeneca's score of 0.80 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Astrazeneca	33 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive

Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

Sanofi presently has a consensus price target of $49.50, suggesting a potential upside of 15.98%. Astrazeneca has a consensus price target of $211.00, suggesting a potential upside of 35.44%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Astrazeneca has a net margin of 17.02% compared to Sanofi's net margin of 8.66%. Astrazeneca's return on equity of 31.45% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Astrazeneca	17.02%	31.45%	13.20%

14.0% of Sanofi shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.35
Astrazeneca	$58.74B	4.11	$10.23B	$6.69	23.29

Summary

Astrazeneca beats Sanofi on 14 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novo Nordisk A/S?

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.0%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.35
Novo Nordisk A/S	$46.80B	4.21	$15.51B	$4.26	10.37

In the previous week, Novo Nordisk A/S had 40 more articles in the media than Sanofi. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 28 mentions for Sanofi. Sanofi's average media sentiment score of 1.09 beat Novo Nordisk A/S's score of 0.35 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Novo Nordisk A/S	26 Very Positive mention(s)	13 Positive mention(s)	5 Neutral mention(s)	16 Negative mention(s)	6 Very Negative mention(s)	Neutral

Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 8.66%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Sanofi currently has a consensus price target of $49.50, suggesting a potential upside of 15.98%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 48.46%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novo Nordisk A/S	2 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to GSK?

Sanofi (NASDAQ:SNY) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Sanofi currently has a consensus target price of $49.50, indicating a potential upside of 15.98%. GSK has a consensus target price of $53.00, indicating a potential upside of 2.77%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts plainly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

14.0% of Sanofi shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Sanofi had 15 more articles in the media than GSK. MarketBeat recorded 28 mentions for Sanofi and 13 mentions for GSK. Sanofi's average media sentiment score of 1.09 beat GSK's score of 0.52 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanofi has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.35
GSK	$43.07B	2.42	$7.54B	$3.20	16.12

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 55.9% of its earnings in the form of a dividend.

Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

GSK has a net margin of 14.56% compared to Sanofi's net margin of 8.66%. GSK's return on equity of 43.23% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
GSK	14.56%	43.23%	11.60%

Summary

Sanofi beats GSK on 10 of the 19 factors compared between the two stocks.

How does Sanofi compare to argenex?

argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

60.3% of argenex shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, Sanofi had 11 more articles in the media than argenex. MarketBeat recorded 28 mentions for Sanofi and 17 mentions for argenex. Sanofi's average media sentiment score of 1.09 beat argenex's score of 0.91 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.44	$1.29B	$26.04	32.43
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.35

argenex has a net margin of 32.19% compared to Sanofi's net margin of 8.66%. argenex's return on equity of 43.59% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Sanofi	8.66%	14.19%	7.95%

argenex currently has a consensus target price of $1,056.89, suggesting a potential upside of 25.15%. Sanofi has a consensus target price of $49.50, suggesting a potential upside of 15.98%. Given argenex's stronger consensus rating and higher probable upside, equities research analysts clearly believe argenex is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Summary

argenex beats Sanofi on 12 of the 16 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNY vs. The Competition

Export

Metric	Sanofi	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$103.47B	$11.45B	$6.80B	$13.02B
Dividend Yield	4.10%	2.74%	2.60%	10.03%
P/E Ratio	22.35	791.59	279.73	25.56
Price / Sales	2.10	948.13	649.61	116.36
Price / Cash	6.10	14.82	28.64	34.82
Price / Book	1.28	10.43	11.12	6.36
Net Income	$8.84B	$2.81B	$3.48B	$347.58M
7 Day Performance	-6.28%	1.93%	2.67%	3.24%
1 Month Performance	-1.11%	-3.06%	-2.70%	-2.00%
1 Year Performance	-11.18%	154.91%	64.43%	21.31%

Sanofi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNY Sanofi	3.6099 of 5 stars	$42.68 -0.6%	$49.50 +16.0%	-8.1%	$103.47B	$49.35B	22.35	74,846	News Coverage Positive News Analyst Upgrade
NVS Novartis	3.1449 of 5 stars	$156.13 +0.7%	$141.20 -9.6%	+33.4%	$295.78B	$54.53B	23.55	75,267	Positive News
AZN Astrazeneca	4.7845 of 5 stars	$170.02 +0.4%	$211.00 +24.1%	N/A	$262.51B	$58.74B	18.28	96,100	Trending News Analyst Downgrade Options Volume
NVO Novo Nordisk A/S	4.2416 of 5 stars	$49.63 +1.8%	$65.56 +32.1%	-2.3%	$217.76B	$46.80B	11.65	69,505	Trending News Earnings Report Upcoming Earnings
GSK GSK	2.91 of 5 stars	$51.97 +1.2%	$53.00 +2.0%	+37.3%	$103.87B	$43.07B	13.50	66,841	Dividend Increase Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNY) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Competitors